Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2IGD1)

Drug Name
MIP-1231 Drug Info
Synonyms
MIP-1232; MIP-1233; MIP-1259; MIP-1260; MIP-1271; MIP-1272; Seprase inhibitors (cancer, imaging); Iodine-131-MIP-1232; Seprase inhibitors (cancer, imaging), Molecular Insight; FAP-alpha antagonists (cancer, imaging), Molecular Insight; Fibroblast-activating protein antagonists (cancer, imaging), Molecular Insight
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
TTD Drug ID
DM2IGD1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prolyl endopeptidase FAP (FAP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talabostat DM1IZ5D Constitutional neutropenia 4B00.0 Phase 3 [2]
BIBH 1 DMHYZEK Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Sibrotuzumab DMT4UC1 Metastatic colorectal cancer 2B91 Phase 2 [3]
NG-641 DMITVHM Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
AMG 506 DMG64PE Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
RG7461 DM5OTGR Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PT630 DM9SY8E Colon cancer 2B90.Z Preclinical [7]
FAP5-DM1 DMYFVZ3 Solid tumour/cancer 2A00-2F9Z Preclinical [8]
ARI-3099 DMIMD0T Discovery agent N.A. Investigative [9]
FE-999040 DM3UCWM Solid tumour/cancer 2A00-2F9Z Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prolyl endopeptidase FAP (FAP) TTGPQ0F SEPR_HUMAN Antagonist [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365).
2 Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9.
3 A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.
4 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
5 Clinical pipeline report, company report or official report of Amgen.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25.
8 Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008 Jul 15;14(14):4584-92.
9 Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77.